| Name | Title | Contact Details |
|---|---|---|
Martin Silverstein |
President and Chief Executive Officer | Profile |
AC Immune SA, a global leader in developing precision medicine for neurodegenerative diseases (incl. Alzheimer & Parkinsons) with cutting-edge technology platforms
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.
American Society of Dermatopathology is a Northbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.